CLAIMS

1. An agent for treating glaucoma or ocular hypertension, comprising an FP agonist as an active ingredient adapted to be administered in combination with timolol or a pharmaceutically acceptable salt thereof, wherein the FP agonist is 2-propanyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoate.

2. The agent according to claim 1, wherein the timolol or a pharmaceutically acceptable salt thereof and 2-propanyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoate are administered separately or concurrently.

3. A pharmaceutical composition for treating glaucoma or ocular hypertension, comprising 2-propanyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoate and timolol or a pharmaceutically acceptable salt thereof adapted to be administered in combination.

4. The pharmaceutical composition according to claim 3, which is an eye drop or an eye ointment.

5. The pharmaceutical composition according to claim 3 or claim 4, which is a compounding agent.

6. Use of an effective amount of 2-propanyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b] oxepin-3-yl}butanoate and timolol or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating glaucoma or ocular hypertension, in a patient in need thereof.

7. Use of an effective amount of 2-propanyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b] oxepin-3-yl}butanoate in the manufacture of a medicament for treating glaucoma or ocular hypertension, in a patient in need thereof, wherein the medicament is to be separately administered with timolol or a pharmaceutically acceptable salt thereof.

8. 2-Propanyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoate for use in treating glaucoma or ocular hypertension in combination with a timolol or a pharmaceutically acceptable salt thereof.